Description: Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Home Page: www.viracta.com
2533 South Coast Highway 101
Cardiff,
CA
92007
United States
Phone:
858 400 8470
Officers
| Name | Title |
|---|---|
| Mr. Mark Andrew Rothera | CEO, President & Director |
| Dr. Darrel P. Cohen M.D., Ph.D. | Chief Medical Officer |
| Dr. Susan Perrine M.D. | Scientific Founder and Consultant |
| Dr. Ronald J. Berenson M.D. | Co-Founder and Consultant |
| Mr. George Hillman | Co-Founder |
| Dr. Thalia Papayannopoulou M.D. | Co-Founder |
| Dr. Robert M. Williams Ph.D. | Co-Founder |
| Dr. Douglas V. Faller M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board |
| Mr. Michael Eric Faerm | Chief Financial Officer |
| Dr. Ayman El-Guindy | Chief Scientific Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6498 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |